Major investor and secret team behind outstanding return on biotech
Following a decade of dramatic ups and downs, Denmark’s most experienced biotech investor has made a remarkable change in strategy – backed by over one billion DKK from the Danish pensions group, ATP. It pays off.
Surrounded by a highly confidential network of international partners and specialists top-executive Florian Schönharting is now – through the consultancy company NB Capital – in the hunt for unique, stock market listed biotech- and pharmaceutical-groups on the larger, global stage in a fund that ATP has put “one billion+” into. The team behind NB Capital has also invested some millions in the fund, which was established in September of 2008. They have invested in approximately 20 companies so far, and most have been re-sold.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Biotech beats the general market in the long run
For abonnenter
He bites his tongue for no one
For abonnenter
